GLAXO WINS EU APPROVAL FOR RELENZA

GlaxoSmithKline said it had received approval in 15 European countries for use of its antiviral drug Relenza in the prevention of influenza types A and B. Scotsman (http://business.scotsman.com/latest.cfm?id=1250272006)